# L_2018088EN.01000101.xml

| 4.4.2018 | EN | Official Journal of the European Union | L 88/1 |
| --- | --- | --- | --- |

4.4.2018

EN

Official Journal of the European Union

L 88/1

---

COMMISSION IMPLEMENTING REGULATION (EU) 2018/523

of 28 March 2018

amending Regulation (EU) No 37/2010 to classify the substance fluazuron as regards its maximum residue limit

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009 laying down Community procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin, repealing Council Regulation (EEC) No 2377/90 and amending Directive 2001/82/EC of the European Parliament and of the Council and Regulation (EC) No 726/2004 of the European Parliament and the Council (1), and in particular Article 14 in conjunction with Article 17 thereof,

Having regard to the opinion of the European Medicines Agency formulated by the Committee for Medicinal Products for Veterinary Use,

Whereas:

| (1) | Article 17 of Regulation (EC) No 470/2009 requires that the maximum residue limit (‘MRL’) for pharmacologically active substances intended for use in the Union in veterinary medicinal products for food-producing animals or in biocidal products used in animal husbandry is established in a Regulation. |
| --- | --- |

(1)

Article 17 of Regulation (EC) No 470/2009 requires that the maximum residue limit (‘MRL’) for pharmacologically active substances intended for use in the Union in veterinary medicinal products for food-producing animals or in biocidal products used in animal husbandry is established in a Regulation.

| (2) | Table 1 of the Annex to Commission Regulation (EU) No 37/2010 (2) sets out the pharmacologically active substances and their classification regarding MRLs in foodstuffs of animal origin. |
| --- | --- |

(2)

Table 1 of the Annex to Commission Regulation (EU) No 37/2010 (2) sets out the pharmacologically active substances and their classification regarding MRLs in foodstuffs of animal origin.

| (3) | Fluazuron is already included in that table as an allowed substance for bovine species, applicable to muscle, fat, liver and kidney, excluding animals producing milk for human consumption. |
| --- | --- |

(3)

Fluazuron is already included in that table as an allowed substance for bovine species, applicable to muscle, fat, liver and kidney, excluding animals producing milk for human consumption.

| (4) | An application for the extension of the existing entry for fluazuron to fin fish has been submitted to the European Medicines Agency (‘EMA’). |
| --- | --- |

(4)

An application for the extension of the existing entry for fluazuron to fin fish has been submitted to the European Medicines Agency (‘EMA’).

| (5) | The EMA, based on the opinion of the Committee for Medicinal Products for Veterinary Use, has recommended the establishment of an MRL for fluazuron in fin fish. |
| --- | --- |

(5)

The EMA, based on the opinion of the Committee for Medicinal Products for Veterinary Use, has recommended the establishment of an MRL for fluazuron in fin fish.

| (6) | According to Article 5 of Regulation (EC) No 470/2009, EMA is to consider using MRLs established for a pharmacologically active substance in a particular foodstuff for another foodstuff derived from the same species, or MRLs established for a pharmacologically active substance in one or more species for other species. |
| --- | --- |

(6)

According to Article 5 of Regulation (EC) No 470/2009, EMA is to consider using MRLs established for a pharmacologically active substance in a particular foodstuff for another foodstuff derived from the same species, or MRLs established for a pharmacologically active substance in one or more species for other species.

| (7) | The EMA has considered that the extrapolation of the entry for fluazuron to tissues of all ruminants except ovine species and to bovine milk is appropriate. |
| --- | --- |

(7)

The EMA has considered that the extrapolation of the entry for fluazuron to tissues of all ruminants except ovine species and to bovine milk is appropriate.

| (8) | Regulation (EU) No 37/2010 should therefore be amended accordingly. |
| --- | --- |

(8)

Regulation (EU) No 37/2010 should therefore be amended accordingly.

| (9) | It is appropriate to grant the stakeholders concerned a reasonable period of time to take measures that may be required to comply with the new MRL. |
| --- | --- |

(9)

It is appropriate to grant the stakeholders concerned a reasonable period of time to take measures that may be required to comply with the new MRL.

| (10) | The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products, |
| --- | --- |

(10)

The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products,

HAS ADOPTED THIS REGULATION:

Article 1

The Annex to Regulation (EU) No 37/2010 is amended as set out in the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

It shall apply from 3 June 2018.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 28 March 2018.

For the Commission

The President

Jean-Claude JUNCKER

---

(1)  
  OJ L 152, 16.6.2009, p. 11.

1

(2)  Commission Regulation (EU) No 37/2010 of 22 December 2009 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin (OJ L 15, 20.1.2010, p. 1).

2

---

ANNEX

In Table 1 of the Annex to Regulation (EU) No 37/2010, the entry for the substance ‘fluazuron’ is replaced by the following:

| Pharmacologically active Substance | Marker residue | Animal Species | MRLs | Target Tissues | Other Provisions (according to Article 14(7) of Regulation (EC) No 470/2009) | Therapeutic Classification |
| --- | --- | --- | --- | --- | --- | --- |
| ‘Fluazuron | Fluazuron | All ruminants except bovine and ovine | 200 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption | Antiparasitic agents/Agents (acting) against ectoparasites’ |
| 7 000 μg/kg | Fat |
| 500 μg/kg | Liver |
| 500 μg/kg | Kidney |
| | Bovine | 200 μg/kg | Muscle | NO ENTRY |
| 7 000 μg/kg | Fat |
| 500 μg/kg | Liver |
| 500 μg/kg | Kidney |
| 200 μg/kg | Milk |
| | Fin fish | 200 μg/kg | Muscle and skin in natural proportions | NO ENTRY |

Pharmacologically active Substance

Marker residue

Animal Species

MRLs

Target Tissues

Other Provisions (according to Article 14(7) of Regulation (EC) No 470/2009)

Therapeutic Classification

‘Fluazuron

Fluazuron

All ruminants except bovine and ovine

200 μg/kg

Muscle

Not for use in animals from which milk is produced for human consumption

Antiparasitic agents/Agents (acting) against ectoparasites’

7 000 μg/kg

Fat

500 μg/kg

Liver

500 μg/kg

Kidney

Bovine

200 μg/kg

Muscle

NO ENTRY

7 000 μg/kg

Fat

500 μg/kg

Liver

500 μg/kg

Kidney

200 μg/kg

Milk

Fin fish

200 μg/kg

Muscle and skin in natural proportions

NO ENTRY

---